8-K: Entera Bio Reports 2025 Results, Advances Oral Peptide Pipeline

Entera Bio announced its full year 2025 financial results and provided key business updates, highlighting progress in its oral peptide development programs, particularly EB613 for osteoporosis.

Summary

• Reported full year 2025 financial results and provided key business updates.
• EB613, an oral anabolic peptide tablet for postmenopausal women with osteoporosis, had its streamlined Phase 3 protocol submitted to the FDA, with comments expected in early Q2 2026.
• FDA aligned in July 2025 on Bone Mineral Density (BMD) as the primary endpoint for EB613 Phase 3, potentially reducing enrollment requirements and accelerating the path to approval by approximately one year.
• EB612, an oral long-acting PTH replacement tablet for hypoparathyroidism, showed positive preclinical data, and an IND filing is intended for late 2026 in partnership with OPKO.
• EB618, an oral OXM (GLP-1/Glucagon) peptide tablet for metabolic syndromes, completed PK/PD validation, with Phase 1 initiation contingent on OPKO's SC injection data by year-end 2026.
• The GLP-2 program for short bowel syndrome demonstrated an 18-fold improvement in plasma half-life over teduglutide in preclinical data.
• Cash and cash equivalents were $14.9 million as of December 31, 2025, including $7.8 million in restricted cash designated for the OPKO collaboration.
• Net loss for the year ended December 31, 2025, was $11.4 million, compared to $9.5 million for the year ended December 31, 2024.
• Research and development expenses increased to $6.0 million in 2025 from $4.5 million in 2024, primarily due to EB613 regulatory and Phase 3 preparation.
• General and administrative expenses increased to $5.5 million in 2025 from $5.1 million in 2024, mainly due to increased consultant fees and compensation.
• Net cash used in operating activities for the year ended December 31, 2025, was $7.4 million.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive update, driven by significant clinical and regulatory progress for EB613 and other pipeline assets, despite increased operating losses typical for a development-stage biotech.

Positives

• FDA alignment on BMD as the primary endpoint for EB613 Phase 3 is a significant regulatory milestone, potentially accelerating approval by one year.
• Submission of a streamlined Phase 3 protocol for EB613 to the FDA indicates clear progress towards clinical trials.
• Positive preclinical data for EB612 (oral LA-PTH) demonstrated a markedly longer plasma half-life and sustained serum calcium elevation for over three days.
• Expanded collaboration with OPKO for EB612 accelerates its path to the clinic, with Entera's Phase 1 expenses expected to be fully funded by existing cash.
• Successful PK/PD validation for oral OXM (EB618) and promising preclinical data for the GLP-2 program highlight the versatility and potential of the N-Tab platform.
• The Next-Gen EB613 single-tablet formulation showed comparable pharmacokinetic exposure to the multi-tablet version and Forteo, allowing direct advancement to Phase 3.
• Strong Phase 2 data for EB613 reinforced early onset of action, showing significant increases in both trabecular and cortical bone indices comparable to injectable treatments.

Negatives

• Net loss increased to $11.4 million in 2025 from $9.5 million in 2024.
• Research and development expenses increased by $1.5 million year-over-year.
• General and administrative expenses increased by $0.4 million year-over-year.
• Unrestricted cash on hand is expected to support operations only through the middle of the third quarter of 2026, indicating a limited cash runway.

Risks

• Changes in the interpretation of clinical data.
• Results of clinical trials may not be favorable.
• The FDA's interpretation and review of clinical trial results and analysis may differ from expectations.
• Unexpected changes in ongoing and planned preclinical development and clinical trials.
• The timing of and ability to make regulatory filings and obtain and maintain regulatory approvals for product candidates.
• Potential disruption and delay of manufacturing supply chains.
• Loss of available workforce resources, either by Entera or its collaboration and laboratory partners.
• Impacts to research and development or clinical activities that Entera may be contractually obligated to provide.
• Overall regulatory timelines may be longer than anticipated.
• The size and growth of the potential markets for product candidates may not meet projections.
• The scope, progress, and costs of developing Entera's product candidates may exceed estimates.
• Reliance on third parties to conduct clinical trials introduces external dependencies.
• Entera's ability to establish and maintain development and commercialization collaborations.
• Operating as a development stage company with limited operating history presents inherent uncertainties.
• Entera's competitive position with respect to other products on the market or in development for various disease categories.
• Entera's ability to continue as a going concern absent access to sources of liquidity.
• Entera's ability to obtain and maintain regulatory approval for any of its product candidates.
• Entera's ability to comply with Nasdaq's minimum listing standards and other requirements of being a public company.
• Entera's intellectual property position and its ability to protect its intellectual property.

Future Outlook

Entera Bio anticipates initiating its EB613 Phase 3 study in late 2026, with topline results expected in the second half of 2028, approximately one year earlier than previously projected due to a streamlined protocol and FDA alignment on endpoints. The company also plans to file an IND for EB612 in late 2026 and expects Phase 1 data from OPKO's injectable OXM formulation by year-end 2026 to enable the oral OXM tablet's Phase 1 initiation. Unrestricted cash is projected to fund operations through mid-Q3 2026.

Management Comments

• "2025 was a landmark year for Entera, our EB613 program and for the osteoporosis community as a whole."
• "We are eager to initiate our important phase 3 study for EB613 and thank the investigator and patient community for their enthusiasm to take part in this mission."
• "While current injectable anabolic or bone forming agents are accepted or accessed by a minority of osteoporosis patients in whom they should be used, our mission with EB613 is to democratize anabolic treatment."
• "EB613 is being developed as the first oral bone building tablet so potentially, every woman and man can have the opportunity to protect their bones whether they are being treated with a primary care practitioner or a specialist."
• "Throughout 2025, we also met every milestone relating to our pipeline and advanced each program with the utmost capital efficiency."
• "Our N-Tab oral peptide platform delivered differentiated preclinical data on LA-PTH, GLP-1/Glucagon and GLP-2 targets in partnership with OPKO Health, Inc. (OPKO). We believe these assets will further drive value for patients with hypoparathyroidism, metabolic syndromes and rare gastrointestinal chronic conditions."

Industry Context

StockSavvy.ai notes that Entera Bio's focus on oral peptide therapies addresses a significant market need for more convenient and accessible treatments, particularly in chronic conditions like osteoporosis and hypoparathyroidism where injectable therapies face patient compliance challenges. The potential for an oral anabolic osteoporosis treatment (EB613) to "democratize" access could be a disruptive force in a market dominated by injectables, aligning with broader industry trends towards patient-centric drug delivery. The collaborations with OPKO Health also indicate a strategic approach to leverage external expertise and funding for pipeline acceleration.

Comparison to Industry Standards

• EB613's Phase 2 data showed significant increases in trabecular and cortical bone indices after six months, comparable to injectable teriparatide (Forteo) and abaloparatide (Tymlos), which are current market leaders for anabolic osteoporosis treatment.
• The GLP-2 tablet candidate demonstrated an 18-fold improvement in plasma half-life over teduglutide (Gattex), the only approved GLP-2 therapy for short bowel syndrome, which requires daily injections. This suggests a potentially superior pharmacokinetic profile and improved patient convenience compared to the current standard.
• The oral OXM (GLP-1/Glucagon) preclinical data showed plasma levels consistent with the highest approved dose of Wegovy (semaglutide), a leading injectable GLP-1 agonist for obesity, indicating potential for competitive efficacy in an oral format.

Stakeholder Impact

• Shareholders: Potential for increased value if clinical programs, especially EB613, succeed in trials and gain regulatory approval. Near-term dilution risk due to potential future capital raise.
• Patients (Osteoporosis, Hypoparathyroidism, Metabolic Syndromes, Short Bowel Syndrome): Potential for novel, more convenient oral treatment options, improving access and compliance compared to current injectable therapies.
• Employees: Continued employment and potential growth opportunities as programs advance.
• OPKO Health, Inc.: Strengthened partnership and shared development costs/ownership for key pipeline assets.

Next Steps

• FDA feedback on EB613 Phase 3 protocol anticipated in late April 2026.
• Initiate EB613 Phase 3 study in late 2026.
• Topline results for EB613 Phase 3 study expected in the second half of 2028.
• File IND application for EB612 in late 2026.
• Initiate oral OXM tablet Phase 1 study after Phase 1 data from injectable formulation (OPK-88006) by year-end 2026.
• Continue development of the GLP-2 tablet candidate.

Key Dates

Recommendation

The company has made significant progress in its clinical pipeline, particularly with EB613, which has a clearer path to Phase 3 and potentially accelerated approval. The expanded collaboration with OPKO also de-risks some development costs. However, the increased net loss and the limited cash runway (mid-Q3 2026 for unrestricted cash) indicate a high likelihood of a future capital raise, which could lead to dilution. Given the promising but still early-stage nature of most programs and the financial needs, a "hold" recommendation is appropriate for investors to monitor the upcoming FDA feedback and capital raise plans.

Keywords

Entera Bio, ENTX, osteoporosis, hypoparathyroidism, metabolic syndromes, short bowel syndrome, oral peptides, drug development, clinical trials, Phase 3, FDA, biotechnology, pharmaceuticals, bone mineral density, GLP-1, Glucagon, PTH, N-Tab platform